AV
Therapeutic Areas
Alnylam Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Patisiran (ONPATTRO) | Hereditary Transthyretin Amyloidosis | Approved |
| Givosiran (GIVLAARI) | Acute Hepatic Porphyria | Approved |
| Lumasiran (OXLUMO) | Primary Hyperoxaluria Type 1 | Approved |
| Inclisiran (LEQVIO) | Hypercholesterolemia | Approved |
| Vutrisiran | Hereditary Transthyretin Amyloidosis | Phase 3 |
| ALN-AGT01 | Hypertension | Phase 1 |
| ALN-KHK | Primary Hyperoxaluria | Phase 3 |
| ALN-APP | Alzheimer's Disease | Phase 1 |
Leadership Team at Alnylam Pharmaceuticals
YG
Yvonne Greenstreet
Chief Executive Officer
JP
Jeffrey Poulton
Chief Financial Officer
TT
Tolga Tanguler
Chief Commercial Officer
PG
Pushkal Garg
Chief Medical Officer
RH
Renta Hutabarat
Executive Vice President, Head of Research
AS
Amy Simon
Chief Human Resources Officer
CR
Christine Regan Lindenboom
Executive Vice President, General Counsel